ten Bosch John Roderick
Known title: SVP of Laboratory OperationsCIK: 0002087126
ten Bosch John Roderick's purchase track record
ten Bosch John Roderick has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/7/2025 | BLLN | $48K | -9.4% | -7.1% | +10.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BLLN | ▼ Sell | Open Market | 1,417 | $149K | 10/5/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,417 | $149K | 10/5/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,416 | $170K | 9/24/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,416 | $151K | 9/21/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,416 | $138K | 9/9/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,417 | $142K | 8/25/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,417 | $132K | 8/10/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,417 | $178K | 7/13/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,417 | $178K | 7/13/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,417 | $178K | 7/13/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,416 | $170K | 6/29/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,416 | $144K | 6/15/2026 | View on chart |
| BLLN | ▼ Sell | Open Market | 1,416 | $144K | 6/15/2026 | View on chart |
| BLLN | ▼ Sell | Other | 37,000 | — | 11/7/2025 | View on chart |
| BLLN | ▼ Sell | Other | 37,000 | — | 11/7/2025 | View on chart |
| BLLN | ▲ Buy | Open Market | 800 | $48K | 11/7/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
BLLN Gets Price Target Hike and New Study Data
BillionToOne reported that its Northstar Response test showed results comparable to or better than tumor-informed assays in a new peer-reviewed study. Guggenheim raised its price target to $128, while other analysts noted rising reimbursement risks. The stock is currently trading near its support level of $95.81.
BLLN Gets Price Target Hike and New Study Data. BillionToOne reported that its Northstar Response test showed results comparable to or better than tumor-informed assays in a new peer-reviewed study. Guggenheim raised its price target to $128, while other analysts noted rising reimbursement risks. The stock is currently trading near its support level of $95.81.